

## BIBLIOGRAFÍA

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. 2002. <http://www.ginasthma.com>.
2. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma: from bronchoconstriction to airways inflammation and remodelling. *Am J Respir Crit Care Med* 2000; 161: 1.720-1.745.
3. Sears MR. Natural history and epidemiology. En: Fitzgerald JM, Ernst P, Boulet LPh, O'Byrne PM, eds. Evidence-based asthma management. Hamilton (Ont): BC Decker Inc., 2001.
4. Janson C, Anto J, Burney P, Chinn S, de Marco R, Heinrich J et al. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. *Eur Resp J* 2001; 18: 598-611.
5. Grupo Español del Estudio Europeo de asma. El Estudio Europeo de asma. La prevalencia de síntomas relacionados con el asma en 5 regiones de España. *Med Clin (Barc)* 1995; 104 (13): 487-492.
6. Grupo Español del Estudio Europeo del Asma. Estudio europeo del asma, prevalencia de hiperreactividad bronquial y asma en jóvenes en 5 regiones de España. Grupo Español del Estudio Europeo del Asma. *Med Clin (Barc)* 1996; 106: 761-767.
7. Sobradillo V, Miravittles M, Jiménez CA, Gabriel R, Viejo JL, Masa JF et al. Estudio IBERPOC en España: prevalencia de síntomas respiratorios habituales y de limitación crónica al flujo aéreo. *Arch Bronconeumol* 1999; 35: 159-166.
8. Sunyer J. Generational increase of self-reported first attack of asthma in fifteen industrialized countries. European Community Respiratory Health Study (ECRHS). *Eur Respir J* 1999; 14: 885-891.
9. Woolcock AJ, Peat JK. Evidence for the increase in asthma worldwide. Ciba Foundation Symposium 1997; 206: 122-134.
10. Braun-Fahrlander C, Riedler J, Herz U, Eder W, Waser M, Grize L et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. *N Engl J Med* 2002; 347: 869-877.
11. Jason C, Chinn S, Jarvis D, Burney P. Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey. *Eur Respir J* 1997; 10: 1.795-1.802.
12. Martínez-Moratalla J, Alma E, Sunyer J, Ramos J, Pereira A, Payo F, Grupo Español de Estudio Europeo del Asma. Identificación y tratamiento de individuos con criterios epidemiológicos de asma en adultos jóvenes de cinco áreas españolas. *Arch Bronconeumol* 1999; 35: 223-228.
13. The International Study of Asthma and Allergies in Childhood. Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. *Lancet* 1998; 351: 1.225-1.232.
14. Magnus P, Jaakkola JJ. Secular trend in the occurrence of asthma among children and young adults: critical appraisal of repeated cross sectional surveys. *Br Med J* 1997; 314(7097): 1.795-1.799.
15. Ng Man Kwong G, Proctor A, Billings C, Duggan R, Das C, Whyte MK et al. Increasing prevalence of asthma diagnosis and symptoms in children is confined to mild symptoms. *Thorax* 2001; 56: 312-314.
16. Ronchetti R, Villa MP, Barreto M, Rota R, Pagani J, Martella S et al. Is the increase in childhood asthma coming to an end? Findings from three surveys of schoolchildren in Rome, Italy. *Eur Respir J* 2001; 17: 881-886.
17. World Health Organization (WHO). Bronchial asthma. WHO fact Sheet N° 206. <http://www.who.int/inf-fs/en/fact206.html>. [Revisado en enero del 2000].
18. Soler M, Chatenoud L, Negri E, La Vecchia C. Trends in asthma mortality in Italy and Spain, 1980-1996. *Eur J Epidemiol* 2001; 17: 545-549.
19. Bellido JB, Sunyer J. Evolución de la mortalidad por asma en los grupos de edad 5-34 y 5-44 años. España, 1975-1991. *Gac Sanit* 1997; 11: 171-175.
20. Esdaile JM, Feinstein AR, Horwitz RI. A reappraisal of the United Kingdom epidemic of fatal asthma. Can general mortality data implicate a therapeutic agent? *Arch Intern Med* 1987; 147: 543-549.
21. Picado C, Montserrat JM, Lloberes P, Luengo M, Serra-Batlle J, Agusti A. Muerte por asma. Análisis de 21 casos. *Med Clin (Barc)* 1986; 87: 653-656.
22. Pearce N, Grainger J, Atkinson M, Crane J, Burgess C, Culling C et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. *Thorax* 1990; 45: 170-175.
23. Ernst P, Spitzer WO, Suissa S, Cockcroft D, Habbick B, Horwitz RI et al. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. *JAMA* 1992; 268: 3.462-3.464.
24. Rea HH, Scragg R, Jackson R, Beaglehole R, Fenwick J, Sutherland DC. A case-control study of deaths from asthma. *Thorax* 1986; 41: 833-839.
25. Anto JM, Sunyer J, Rodríguez-Roisin R, Suárez-Cervera M, Vázquez L. Community outbreaks of asthma associated with inhalation of soybean dust. Toxicoepidemiological Committee. *N Engl J Med* 1989; 320: 1.097-1.102.
26. Weiss KB. Seasonal trends in US asthma hospitalizations and mortality. *JAMA* 1990; 263: 2.323-2.328.
27. O'Hollaren MT, Yunginger JW, Offord KP, Somers MJ, O'Connell EJ, Ballard DJ et al. Exposure to an aeroallergen as a possible precipitating factor in respiratory arrest in young patients with asthma. *N Engl J Med* 1991; 324: 359-363.
28. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. *N Engl J Med* 1992; 326: 862-866.
29. Thompson S. On the social cost of asthma. *Eur J Respir Dis* 1984; 65: 185-191.
30. Mellis CM, Peat JK, Bauman AE, Woolcock AJ. The cost of asthma in New South Wales. *Med J Aust* 1991; 155: 522-528.
31. Serra-Batlles J, Plaza V, Morejón E, Comella A, Brugués J. The costs of asthma according to the degree of severity. *Eur Respir J* 1998; 12: 1.322-1.326.
32. Plaza V, Serra-Batlles J, Morejón E, Ferrer M. Quality of life and economics features of elderly asthmatics. *Respiration* 2000; 67: 65-70.
33. Blainey D, Lomas D, Beale A, Partridge M. The costs of acute asthma: how much is preventable? *Health Trends* 1991; 22: 151-153.
34. Clarck NM, Feldman CH, Evans D, Levinson MJ, Wasilewski, Mellins RB. The impact of health education on frequency and cost of health care use by low income children with asthma. *J Allergy Clin Immunol* 1986; 78: 108-115.
35. Kelly CS, Anderssen CL, Pestian JP, Wenger AD, Finbch AB, Strobe GL et al. Improved outcomes for hospitalized asthmatic children using a clinical pathway. *Ann Allergy Asthma Immunol* 2000; 84: 509-516.
36. Martínez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. *N Engl J Med* 1995; 332: 133-138.
37. Reijonen T, Korppi M, Kuikka L, Remes K. Anti-inflammatory therapy reduces wheezing after bronchiolitis. *Arch Pediatr Adolesc Med* 1996; 150: 512-517.
38. Clough JB, Keeping KA, Edwards LC, Freeman WM, Warner JA, Warner JO. Can we predict which wheezy infants will continue to wheeze? *Am J Respir Crit Care Med* 1999; 160 (5Pt1): 1.473-1.480.
39. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. *Br Med J* 1996; 312: 1.195-1.199.
40. Wennergren G, Kristjánsson S. Wheezing in infancy and its long-term consequences. *Eur Resp Mon* 2002; 7: 116-130.
41. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. *Thorax* 2003; 58 (Supl 1): 1-94.
42. Walsh LJ, Wong CA, Cooper S, Guhan AR, Pringle M, Tattersfield AE. Morbidity from asthma in relation to regular treatment: a community based study. *Thorax* 1999; 54: 296-300.

43. Sandford A, Weir T, Pare P. The genetics of asthma. *Am J Respir Crit Care Med* 1996; 153(6 Pt 1): 1.749-1.765.
44. Wjst M, Fischer G, Immervoll T, Jung M, Saar K, Rueschendorf F et al. A genome-wide search for linkage to asthma. German Asthma Genetics Group. *Genomics* 1999; 58: 1-8.
45. Koppelman GH, Los H, Postma DS. Genetic and environment in asthma: the answer of twin studies. *Eur Respir J* 1999; 13: 2-4.
46. Martínez FD, Holberg CJ, Halonen M, Morgan WJ, Wright AL, Taussig LM. Evidence for Mendelian inheritance of serum IgE levels in Hispanic and non-Hispanic white families. *Am J Hum Genet* 1994; 55: 555-565.
47. Cookson WO. Asthma genetics. *Chest* 2002; 121 (3 Supl): 75-135.
48. Los H, Koppelman GH, Postma DS. The importance of genetic influences in asthma. *Eur Respir J* 1999; 14: 1.210-1.227.
49. Sengler C, Lau S, Wahn U, Nickel R. Interactions between genes and environmental factors in asthma and atopy: new developments. *Respir Res* 2002; 3(1): 7.
50. Wahn U, Lau S, Bergmann R, Kulig M, Forster J, Bergmann K et al. Indoor allergen exposure is a risk factor for sensitization during the first three years of life. *J Allergy Clin Immunol* 1997; 99(6 Pt 1): 763-769.
51. Sporik R, Ingram JM, Price W, Sussman JH, Honsinger RW, Platts-Mills TA. Association of asthma with serum IgE and skin test reactivity to allergens among children living at high altitude. Tickling the dragon's breath. *Am J Respir Crit Care Med* 1995; 151: 1.388-1.392.
52. Strachan DP. Hay fever, hygiene, and household size. *Br Med J* 1989; 299(6710): 1.259-1.260.
53. Ball TM, Castro-Rodríguez JA, Griffith KA, Holberg CJ, Martínez FD, Wright AL. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. *N Engl J Med* 2000; 343: 538-543.
54. Riedler J, Braun-Fahrlander C, Eder W, Schreuer M, Wasser M, Maisch S et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. *Lancet* 2001; 358: 1.129-1.133.
55. Gereda JE, Leung DY, Thatayatikom A, Streib JE, Price MR, Klinnert MD et al. Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitization in infants at high risk of asthma. *Lancet* 2000; 355: 1.680-1.683.
56. Isolauri E. Probiotics in the prevention and treatment of allergic disease. *Pediatr Allergy Immunol* 2001; 12 (Supl): 1.456-1.459.
57. Matricardi PM, Rosmini F, Ferrigno L, Nisini R, Rapicetta M, Chionne P et al. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. *Br Med J* 1997; 314: 999-1.003.
58. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999; 354: 541-545.
59. Britton J, Pavord I, Richards K, Wisniewski A, Knox A, Lewis S et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. *Lancet* 1994; 344: 357-362.
60. Greene LS. Asthma, oxidant stress, and diet. *Nutrition* 1999; 15: 899-907.
61. Hodge L, Salome CM, Peat JK, Haby MM, Xuan W, Woolcock AJ. Consumption of oily fish and childhood asthma risk. *Med J Aust* 1996; 164: 137-140.
62. Pistelli R, Forastiere F, Corbo GM, Dell'Orco V, Brancato G, Agabiti N et al. Respiratory symptoms and bronchial responsiveness are related to dietary salt intake and urinary potassium excretion in male children. *Eur Respir J* 1993; 6: 517-522.
63. Castro-Rodríguez JA, Holberg CJ, Morgan WJ, Wright AL, Martínez FD. Increased incidence of asthmalike symptoms in girls who become overweight or obese during the school years. *Am J Respir Crit Care Med* 2001; 163: 1.344-1.349.
64. Oddy WH, Holt PG, Sly PD, Read AW, Landau LI, Stanley FJ et al. Association between breast feeding and asthma in 6 year old children: findings of a prospective birth cohort study. *Br Med J* 1999; 319: 815-819.
65. Wright AL, Holberg CJ, Taussig LM, Martínez FD. Factors influencing the relation of infant feeding to asthma and recurrent wheeze in childhood. *Thorax* 2001; 56: 192-197.
66. Strachan DP, Cook DG. Health effects of passive smoking. 6. Parental smoking and childhood asthma: longitudinal and case-control studies. *Thorax* 1998; 53(3): 204-212.
67. García-Marcos L, Guillen JJ, Dinwiddie R, Guillen A, Barbero P. The relative importance of socio-economic status, parental smoking and air pollution (SO<sub>2</sub>) on asthma symptoms, spirometry and bronchodilator response in 11-year-old children. *Pediatr Allergy Immunol* 1999; 10(2): 96-100.
68. Nowak D, Heinrich J, Jorres R, Wassmer G, Berger J, Beck E et al. Prevalence of respiratory symptoms, bronchial hyperresponsiveness and atopy among adults: west and east Germany. *Eur Respir J* 1996; 9: 2.541-2.552.
69. Salvi S, Holgate ST. Mechanisms of particulate matter toxicity. *Clin Exp Allergy* 1999; 29: 1.187-1.194.
70. Tuffaha A, Gern JE, Lemanske RF Jr. The role of respiratory viruses in acute and chronic asthma. *Clin Chest Med* 2000; 21: 289-300.
71. Evans D, Levison MJ, Feldman CH, Clark NM, Wasilewski Y, Levin B et al. The impact of passive smoking on emergency room visits of urban children with asthma. *Am Rev Respir Dis* 1987; 135: 567-572.
72. Norris G, Larson T, Koenig J, Claiborn C, Sheppard L, Finn D. Asthma aggravation, combustion, and stagnant air. *Thorax* 2000; 55: 466-470.
73. Khot A, Burn R, Evans N, Lenney W, Storr J. Biometeorological triggers in childhood asthma. *Clin Allergy* 1988; 18: 351-358.
74. Clark CJ, Cochrane LM. Physical activity and asthma. *Curr Opin Pulm Med* 1999; 5: 68-75.
75. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. *J Allergy Clin Immunol* 1999; 104: 5-13.
76. Harding SM, Guzzo MR, Richter JE. The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. *Am J Respir Crit Care Med* 2000; 162: 34-39.
77. Holt PG, Stumbles PA. Regulation of immunologic homeostasis in peripheral tissues by dendritic cells: the respiratory tract as a paradigm. *J Allergy Clin Immunol* 2000; 105: 421-429.
78. Lambrecht BN, de Veerman M, Coyle AJ, Gutiérrez-Ramos JC, Thielemans K, Pauwels RA. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. *J Clin Invest* 2000; 106: 551-559.
79. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. *N Engl J Med* 2002; 346: 1.699-1.705.
80. Boyce JA. Mast cells: beyond IgE. *J Allergy Clin Immunol* 2003; 111: 24-33.
81. Akers IA, Parsons M, Hill MR, Hollenberg MD, Sanjar S, Laurent GJ, McAnulty RJ. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. *Am J Physiol Lung Cell Mol Physiol* 2000; 278: L193-201.
82. Prescott SL, Macaubas C, Smallacombe T, Holt BJ, Sly PD, Holt PG. Development of allergen-specific T-cell memory in atopic and normal children. *Lancet* 1999; 353: 196-200.
83. Gleich GJ. Mechanisms of eosinophil-associated inflammation. *J Allergy Clin Immunol* 2000; 105: 651-663.
84. Robinson DS, Kay AB, Wardlaw AJ. Eosinophils. *Clin Allergy Immunol* 2002; 16: 43-75.
85. Holgate ST, Lackie P, Wilson S, Roche W, Davies D. Bronchial epithelium as a key regulator of airway allergen sensitization and remodeling in asthma. *Am J Respir Crit Care Med* 2000; 162(3 Pt 2): S113-117.
86. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma: an ultrastructural, quantitative study and correlation with hyperreactivity. *Am Rev Respir Dis* 1989; 140: 1.745-1.753.
87. Ohashi Y, Motojima S, Fukuda T, Makino S. Airways hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma. *Am Rev Respir Dis* 1992; 145: 1.469-1.476.

88. Berkman N, Robichaud A, Krishnan VL, Roesems G, Robbins R, Jose PJ et al. Expression of RANTES in human airway epithelial cells: effect of corticosteroids and interleukin-4, -10 and -13. *Immunology* 1996; 87: 599-603.
89. Roche WR, Beasley R, Williams JH, Holgate ST. Subepithelial fibrosis in the bronchi of asthmatics. *Lancet* 1989; 1: 520-524.
90. Ollerenshaw SL, Woolcock AJ. Characteristics of inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. *Am Rev Respir Dis* 1992; 145: 922-927.
91. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. *Am J Respir Crit Care Med* 1997; 156: 229-233.
92. Vrugt B, Wilson S, Bron A, Holgate ST, Djukanovic R, Aalbers R. Bronchial angiogenesis in severe glucocorticoid-dependent asthma. *Eur Respir J* 2000; 15: 1.014-1.021.
93. Shimura S, Andoh Y, Haraguchi M, Shirato K. Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. *Eur Respir J* 1996; 9: 1.395-1.401.
94. Sheehan JK, Richardson PS, Fung DC, Howard M, Thornton DJ. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. *Am J Respir Cell Mol Biol* 1995; 13: 748-756.
95. Hogg JC. Pathology of asthma. *J Allergy Clin Immunol* 1993; 9: 21-25.
96. Wiggs BR, Moreno R, Hogg JC, Hilliam C, Pare PD. A model of the mechanics of airway narrowing. *J Appl Physiol* 1990; 69: 849-860.
97. Redington AE, Roche WR, Madden J, Frew AJ, Djukanovic R, Holgate ST et al. Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge. *J Allergy Clin Immunol* 2001; 107: 384-387.
98. Brewster CE, Howarth PH, Djukanovic R, Wilson J, Holgate ST, Roche WR. Myofibroblasts and subepithelial fibrosis in bronchial asthma. *Am J Respir Cell Mol Biol* 1990; 3: 507-511.
99. Laitinen A, Altraja A, Kampe M, Linden M, Virtanen I, Laitinen LA. Tenascin is increased in airway basement membrane of asthmatics and decreased by an inhaled steroid. *Am J Respir Crit Care Med* 1997; 156: 951-958.
100. Wilson JW, Li X. The measurement of reticular basement membrane and submucosal collagen in the asthmatic airway. *Clin Exp Allergy* 1997; 27: 363-371.
101. Fredberg JJ. Airway smooth muscle in asthma: flirting with disaster. *Eur Respir J* 1998; 12: 1.252-1.256.
102. Crapo R. Guidelines for Methacholine and Exercise Challenge Testing 1999. *Am J Respir Crit Care Med* 2000; 161: 309-329.
103. Woolcock AJ, Salome CM, Yan K. The shape of the dose-response curve to histamine in asthmatic and normal subjects. *Am Rev Respir Dis* 1984; 130: 71-75.
104. Álvarez MJ, Olaguibel JM, García BE, Rodríguez A, Tabar AI. Airway inflammation in asthma and perennial allergic rhinitis. Relationship with non-specific bronchial hyperresponsiveness and maximal airway narrowing. *Allergy* 2000; 55: 355-362.
105. Brusasco V, Crimi E, Pellegrino R. Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. *Thorax* 1998; 53: 992-998.
106. Blackie SP, al-Majed S, Staples CA, Hilliam C, Pare PD. Changes in total lung capacity during acute spontaneous asthma. *Am Rev Respir Dis* 1990; 142: 79-83.
107. Chhabra SK. Forced vital capacity, slow vital capacity, or inspiratory vital capacity: which is the best measure of vital capacity? *J Asthma* 1998; 35: 361-365.
108. McFadden ER Jr, Lyons HA. Serial studies of factors influencing airway dynamics during recovery from acute asthma attacks. *J Appl Physiol* 1969; 27: 452-459.
109. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. *N Engl J Med* 1998; 339: 1.194-1.200.
110. Wagner EM, Bleecker ER, Permutt S, Liu MC. Direct assessment of small airways reactivity in human subjects. *Am J Respir Crit Care Med* 1998; 157: 447-452.
111. Ferrer A, Roca J, Wagner PD, López FA, Rodríguez-Roisin R. Airway obstruction and ventilation-perfusion relationships in acute severe asthma. *Am Rev Respir Dis* 1993; 147: 579-584.
112. Kraft M, Pak J, Martin RJ, Kaminsky D, Irvin CG. Distal lung dysfunction at night in nocturnal asthma. *Am J Respir Crit Care Med* 2001; 163: 1.551-1.556.
113. Sanchis J, Casan P, Castillo J, González N, Palenciano L, Roca J. Normativa para la práctica de la espirometría forzada. *Arch Bronconeumol* 1989; 25: 132-142.
114. Casan P, Burgos F, Barberá JA, Giner J. Espirometría. En: Manual SEPAR de procedimientos. Coordinadores: Burgos F, Casan P. Procedimientos de evaluación de la función pulmonar. SEPAR. Madrid: EGRAF, S.A., 2002.
115. Casan P, Roca J, Sanchis J. Spirometric response to a bronchodilator. Reference values for healthy children and adolescents. *Bull Eur Physiopathol Respir* 1983; 19: 567-569.
116. Pardo C, Fuertes J, Nerin I, González Pérez-Yarza E. Cuando se considera positivo el test de broncodilatación. *An Esp Pediatr* 2002; 57: 5-11.
117. Parameswaran K, Belda J, Sears MR. Use of peak flow variability and metacholine responsiveness in predicting changes from pre-test diagnosis of asthma. *Eur Respir J* 1999; 14: 1.358-1.362.
118. Quanjer PH, Lebowitz MD, Gregg I, Miller MR, Pederセン OF. Peak expiratory flow: conclusions and recommendations of a Working Party of the European Respiratory Society. *Eur Respir J* 1997; 24(Supl): 2S-8S.
119. Thiadens HA, de Bock GH, Dekker FW. Value of measuring diurnal peak flow variability in the recognition of asthma: a study in general practice. *Eur Respir J* 1998; 12: 842-847.
120. Perpiñá M, Pellicer C, de Diego A, Compte L, Macián V. Diagnostic value of the bronchial provocation test with metacholine in asthma. A Bayesian analysis approach. *Chest* 1993; 104: 149-154.
121. Goldstein MF, Veza BA, Dunsky EH, Dvorin DJ, Belecanech GA, Haralabatos IC. Comparison of peak diurnal expiratory flow variation, postbronchodilator FEV<sub>1</sub> responses, and metacholine inhalation challenges in the evaluation of suspected asthma. *Chest* 2001; 119: 1.001-1.010.
122. American Thoracic Society. Guidelines for metacholine and exercise challenge testing. *Am J Respir Crit Care Med* 1999; 161: 309-329.
123. American Thoracic Society. Standardization of spirometry. 1994 Update. *Am J Respir Crit Care Med* 1995; 152: 1.107-1.136.
124. Bardagí S, Calvo E, Casan P, de Diego A, Cimas J, Hernández E et al. Recomendaciones para la atención del paciente con asma. Recomendaciones SEPAR-semFyc. *Arch Bronconeumol* 1998; 34: 394-399.
125. Arets HGM, Brackel HJL, van der Ent CK. Forced expiratory manoeuvres in children: do they meet ATS end ERS criteria for spirometry? *Eur Respir J* 2001; 18: 655-660.
126. Enright PL, Linn WS, Avol EL, Margolis HG, Gong H, Peters JM. Quality of spirometry performance in children and adolescents. *Chest* 2000; 118: 665-671.
127. Godfrey S, Springer C, Bar-Yishay E, Avital A. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults. *Eur Respir J* 1999; 14: 659-668.
128. Nielsen KG, Bisgaard H. Discriminative capacity of bronchodilator response measured with three different lung function techniques in asthmatic and healthy children aged 2 to 5 years. *Am J Respir Crit Care Med* 2001; 164: 554-559.
129. Hellinckx J, de Boeck K, Bande-Knops J, van der Poel M, Demedts M. Bronchodilator response in 3-6.5 years old healthy and stable asthmatic children. *Eur Respir J* 1998; 12: 438-443.
130. Gapa M, Collin AA, Goetz I, Stocks J. Passive respiratory mechanics: the occlusion techniques. *Eur Respir J* 2002; 17: 141-148.

131. Merkus PJ, Arets HG, Joosten T, Siero A, Brouha M et al. Measurements of interrupter resistance: reference values for children 3-13 years of age. *Eur Respir J* 2002; 20: 907-911.
132. Jones M, Castile R, Davis S, Kisling J, Filbrun D et al. Forced expiratory flows and volumes in infants. Normative data and lung growth. *Am J Respir Crit Care Med* 2000; 161: 353-359.
133. Hoo AF, Dezateux C, Hanrahan JP, Cole TJ, Tepper RS, Stocks J. Sex-specific prediction equations for  $V_{\max}$  (FRC) in infancy: a multicenter collaborative study. *Am J Respir Crit Care Med* 2002; 165: 1.084-1.092.
134. Goldstein AB, Castile R, Davis SD, Filbrun DA, Flucke RL et al. Bronchodilator responsiveness in normal infants and young children. *Am J Respir Crit Care Med* 2001; 164: 447-454.
135. Holt PG, Macaubas C, Strumbles PA, Sly PD. The role of allergy in the development of asthma. *Nature* 1999; 402 (Supl): B12-17.
136. Malling HJ. Methods of skin testing. *Allergy* 1993; 14: 55-66.
137. Netherlands Society of Allergology, Committee on Skin Test Standardization. Report on skin test standardization. *Clin Allergy* 1988; 18: 305-310.
138. Belda J, Casan P, Sanchís J. El esputo inducido en el asma. En: Belda J, Casan P, Sanchís J, eds. *Procedimientos de laboratorio. Clínica d'Asma i d'Al·lèrgia*. Departament de Pneumologia. Hospital de la Santa Creu i de Sant Pau. Barcelona: Editorial Preimpresión Directa SL, 2001.
139. Djukanovic R, Sterk PJ, Fahy JV, Hargreave FE. Standardised methodology of sputum induction and processing. *Eur Respir J* 2002; 20 (Supl 37): 1s-2s.
140. Recommendations for standardised procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children. *Am J Respir Crit Care Med* 1999; 160: 2.104-2.117.
141. Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV, Barnes PJ. Dose-dependent onset and cessation of action of inhaled budesonide on exhaled nitric oxide and symptoms in mild asthma. *Thorax* 2002; 57: 889-896.
142. Parameswaran K, Hargreave FE. Growing global interest in the non-invasive measurement of airway inflammation. *Eur Respir J* 2002 (Supl 38): 93S.
143. Grupo de trabajo para el estudio de la enfermedad asmática en el niño. *Asma. An Esp Pediatr* 2002; 56 (Supl 7): 37-43.
144. Turner MO, Taylor D, Bennett R, Fitzgerald M. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. *Am J Respir Crit Care Med* 1998; 157: 540-546.
145. Emerman CL, Cydulka R. Effect of pulmonary function test on the management of acute asthma. *Arch Intern Med* 1995; 155: 2.225-2.228.
146. Cates C. Holding chambers versus nebulizers for beta-agonist treatment of acute asthma. *Cochrane Database Sys Rev* 2000(3). CD001491.
147. Travers A, Jones AP, Kelly K. Intravenous beta2agonists for acute asthma in the emergency department. *Cochrane Database Sys Rev* 2001(3).
148. Rodrigo G, Rodrigo G, Burstchin O. Ipratropium bromide in acute adult severe asthma: a metaanalysis of randomized controlled trials. *Am J Med* 1999; 107: 363-370.
149. Rowe BH, Keller JL, Oxmann AD. Effectiveness of steroid therapy in acute exacerbations of asthma: a metaanalysis. *Am J Emerg Med* 1992; 10: 301-310.
150. Manser R, Reid D, Abransson M. Corticosteroids for acute severe asthma in hospitalized patients. *Cochrane Database Sys Rev* 2001(3).
151. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA. Magnesium sulfate for treating acute asthmatic exacerbations of acute asthma in emergency department. *Cochrane Database Sys Rev* 2001(2). CD001490.
152. National Guideline Clearinghouse. Cincinnati Children's Hospital Medical Center. Evidence based clinical practice guideline for managing an acute exacerbation of asthma. Cincinnati (OH): Cincinnati Children's Hospital Medical Center, 2002.
153. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma (Cochrane Review). En: *The Cochrane Library* (4). Oxford: Update Software, 2000.
154. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma (Cochrane Review). En: *The Cochrane Library* (4). Oxford: Update Software, 2000.
155. Plotnick LH, Ducharme FM. Should inhaled anticholinergics be added to beta-2-agonists for treating acute childhood and adolescent asthma? A systematic review. *Br Med J* 1998; 317: 971-977.
156. Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. *Arch Pediatr Adolesc Med* 2000; 154: 979-983.
157. Fischl MA, Pitchenik A, Gardner LB. An index predicting relapse and need for hospitalization in patients with acute asthma. *N Engl J Med* 1981; 305: 782-789.
158. Lim TK, Chin NK, Lee KH, Stebbings AM. Early discharge of patients hospitalized with acute asthma: a controlled study. *Respir Med* 2000; 94: 1.234-1.240.
159. Boulet LP, Becker A, Berubé D, Beveridge R, Ernst P, on behalf of the Canadian Asthma Consensus Group. Summary of recommendations from the Canadian Asthma Consensus report, 1999. *CMAJ* 1999; 161(11 Supl): S1-S12.
160. Godfrey S, Bar-Yishay E. Exercise-induced asthma revisited. *Respir Med* 1993; 87: 331-344.
161. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. *N Engl J Med* 1997; 337: 1.405-1.411.
162. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. *Am J Respir Crit Care Med* 1996; 153: 1.481-1.488.
163. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. *Br Med J* 1999; 319: 87-90.
164. Vaquerizo MJ, Casan P, Castillo J, Perpiñá M, Sanchís J, Sobradillo V et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. *Thorax* 2003; 58: 204-210.
165. Toogood JH, Baskerville JC, Jennings B, Lefcoe NM, Johansson SA. Influence of dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. *Am Rev Respir Dis* 1989; 140: 624-628.
166. Malo JL, Cartier A, Merland N, Ghezzi H, Burek A, Morris J et al. Four times-a-day dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. *Am Rev Respir Dis* 1989; 140: 624-628.
167. Villa-Asensi JR, Pérez-Frías J. Tratamiento farmacológico del asma. En: García-Marcos L, ed. *Asma en Pediatría*. Barcelona: Edipharma, 2002; 153-183.
168. North of England evidence based guideline development project summary version of evidence based guideline for the primary care management in adults. North of England Asthma guideline Development Group. *Br Med J* 1996; 312: 762-766.
169. Simons FE, Villa JR, Lee BW, Teper AM, Aristizabal G, Laessig W et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. *J Pediatr* 2001; 138: 694-698.
170. Newman SP, Clark SW. Therapeutic aerosols. 1- Physical and practical considerations. *Thorax* 1983; 38: 881-886.
171. Clark SW, Newman SP. Therapeutic aerosols. 2- Drugs available by the inhaled route. *Thorax* 1984; 39: 1-7.
172. Cates CJ, Jefferson TO, Bara AI, Rowe BH. Vaccines for preventing influenza in people with asthma (Cochrane Review). En: *The Cochrane Library* (1). Oxford: Update Software, 2003.

173. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. *Thorax* 1993; 48: 233-238.
174. Plaza V, Casan P, Diego A, Gladiz JB, López Viñas A, Manresa F. Recomendaciones para la utilización de fármacos inhalados. *Arch Bronconeumol* 1996; 32(Supl): 8-9.
175. Giner J, Basualdo LV, Casan P, Hernández C, Macián V, Martínez I et al. Normativa sobre la utilización de fármacos inhalados. Recomendaciones SEPAR. *Arch Bronconeumol* 2000; 36: 34-43.
176. Giner J, Macián V, Hernández C y grupo EDEN. Estudio multicéntrico y prospectivo de «educación y enseñanza» del procedimiento de inhalación en pacientes respiratorios (estudio EDEN). *Arch Bronconeumol* 2002; 38: 300-305.
177. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. *Eur Respir J* 2002; 19: 246-251.
178. Haro M, Lázaro C, Marín-Barbueno C, Andicoberry MJ, Martínez MD. Utilidad de la enseñanza del manejo del cartucho presurizado y el sistema Turbuhaler® en los pacientes hospitalizados. *Arch Bronconeumol* 2002; 38: 306-310.
179. NICE. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. Technology appraisal guidance n° 10. NHS National Institute for Clinical Excellence, 2000. En: <http://www.nice.org.uk>
180. Bousquet J, Hejjaoui A, Michel FB. Specific immunotherapy in asthma. *J Allergy Clin Immunol* 1990; 86: 292-305.
181. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. *Am J Respir Crit Care Med* 1995; 151: 969-974.
182. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma (Cochrane Review) En: *The Cochrane Library* (1). Oxford: Update Software, 2003.
183. WHO Position Paper: allergen immunotherapy: therapeutic vaccines for allergic diseases. *Allergy* 1998; 53(Supl): 1-42.
184. Bousquet J, Lockey RF, Malling HJ, Álvarez-Cuesta E, Canonica, Chapman MD et al. Allergen immunotherapy: vaccines for allergic diseases. World Health Organization. *Allergy* 1998; 44: 2-42.
185. Li JT, Lockey RF, Bernstein IL, Portnoy JM, Nicklas RA. Allergen immunotherapy: a practice parameter. *Ann Allergy Asthma Immunol* 2003; 90: S1-S40.
186. Plaza V, Giner J, Gómez J, Casan P, Sanchís J. Conocimientos y destreza en el manejo del inhalador Turbuhaler por parte del personal sanitario. *Arch Bronconeumol* 1997; 33: 113-117.
187. Plaza V, Sanchís J y CESEA Group. Medical personnel and patient skill in the use of metered dose inhalers: a multicentric study. *Respiration* 1998; 65: 195-198.
188. Serra-Batlles J, Plaza V, Badiola C, Morejón E. Patient perception and acceptability of multidose dry powder inhalers: a randomized crossover comparison of Diskus/Accuhaler with Turbuhaler. *J Aerosol Med* 2002; 15: 59-64.
189. Carrión F, Maya M, Montan I, Díaz J, Marín J. Técnica de inhalación en los pacientes con enfermedades respiratorias crónicas. *Arch Bronconeumol* 2000; 36: 236-240.
190. Leach C, Davidson P, Hasselquist B, Boudreau R. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. *Chest* 2002; 122: 510-516.
191. Gotzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma (Cochrane Review). En: *The Cochrane Library* (1). Oxford: Update Software, 2003.
192. Ehnert B, Lau-Schadendorf S, Weber A, Buettner P, Schou C, Whan U. Reducing domestic exposure to dust mite allergen reduces bronchial hyperreactivity in sensitive children with asthma. *J Allergy Clin Immunol* 1993; 90: 135-138.
193. Woodfolk JA, Hayden ML, Couture N, Platts-Mills TAE. Chemical treatment of carpets to reduce allergen: comparison of the effects of tannic acid and other treatments on proteins derived from dust mites and cats. *J Allergy Clin Immunol* 1995; 96: 325-333.
194. Halonen M, Stern DA, Wright AL, Taussig LM, Martínez FD. *Alternaria* as a major allergen for asthma in children raised in a desert environment. *Am J Respir Crit Care Med* 1997; 155: 1.356-1.361.
195. Wood RA, Chapman MD, Adkinson NF Jr, Eggleston PA. The effect of cat removal on allergen content in household-dust samples. *J Allergy Clin Immunol* 1989; 83: 730-734.
196. de Blay F, Chapman MD, Platts-Mills TAE. Airborne cat allergen (Fel d 1): environmental control with the cat in situ. *Am Rev Respir Dis* 1991; 143: 1.334-1.339.
197. Kilburn S, Lasserson TJ, McKean M. Pet allergen control measures for allergic asthma in children and adults (Cochrane Review). En: *The Cochrane Library* (1). Oxford: Update Software, 2003.
198. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavins RG, Gergen P et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. *N Engl J Med* 1997; 336: 1.356-1.363.
199. Eggleston PA, Wood RA, Rand C, Nixon WJ, Chen PH, Lukk P. Removal of cockroach allergen from inner-city homes. *J Allergy Clin Immunol* 1999; 104: 842-846.
200. McWhorter, Polis MA, Kaslow RA. Occurrence, predictors, and consequences of adult asthma in NHANESI and follow-up survey. *Am Rev Respir Dis* 1989; 139: 721-724.
201. American Thoracic Society. Cigarette smoking and health. American Thoracic Society. *Am J Respir Crit Care Med* 1996; 153: 861-865.
202. Jiménez Ruiz CA, Solano S, González JM, Ruiz M, Flórez S, Ramos A et al. Normativa para el tratamiento del tabaquismo (SEPAR). *Arch Bronconeumol* 1999; 335: 499-506.
203. Jiménez Ruiz CA, Barrueco M, Solano S, Torrecilla M, Dominguez M, Díaz-Maroto et al. Recomendaciones en el abordaje diagnóstico y terapéutico del tabaquismo. Documento de consenso. *Arch Bronconeumol* 2003; 39: 35-41.
204. Linde K, Jobst KA. Homeopathy for chronic asthma (Cochrane Review). En: *The Cochrane Library* (1). Oxford: Update Software, 2003.
205. Linde K, Jobst K, Panton J. Acupuncture for chronic asthma (Cochrane Review). En: *The Cochrane Library* (1). Oxford: Update Software, 2003.
206. Medici TC, Grebski E, Wu J, Hinz G, Wuthrich B. Acupuncture and bronchial asthma: a long-term randomized study of the effects of real versus sham acupuncture compared to controls in patients with bronchial asthma. *J Altern Complement Med* 2002; 8: 737-750.
207. Huntley A, Ernst E. Herbal medicines for asthma: a systematic review. *Thorax* 2000; 55: 925-929.
208. Steurer-Stey C, Russi EW, Steurer J. Complementary and alternative medicine in asthma: do they work? *Swiss Med Wkly* 2002; 132: 338-344.
209. Ernst P, Fitzgerald JM, Spier S. Canadian Asthma Consensus Conference Summary of recommendations. *Can Respir J* 1996; 3: 89-100.
210. Partridge MR. Patient education. En: O'Byrne P, Thomson NC, eds. *Manual of asthma management*. WB Saunders, 1995; 378-392.
211. Partridge MR, Hill SR. Enhancing care for people with asthma: the role of communication, education, training and self management. *Eur Respir J* 2000; 16: 333-348.
212. Evans D. To help patients control asthma the clinician must be a good listener and teacher. *Thorax* 1993; 48: 685-687.
213. Mellins RB, Evans D, Zimmerman B, Clark NM. Patient compliance. Are we wasting our time and don't know it? *Am Rev Respir Dis* 1992; 146: 1.376-1.377.
214. Gibson PG, Coughlan J, Wilson AJ, Abramson M, Bauman A, Hensley MJ et al. Self-management education and regular practitioner review for adults with asthma (Cochrane Review). En: *The Cochrane Library* (4). Oxford: Update Software, 2002.
215. Powell H, Gibson PG. Options for self-management education for adults with asthma (Cochrane Review). En: *The Cochrane Library* (1). Oxford: Update Software, 2003.

216. Gibson PG, Coughlan J, Wilson AJ, Abramson M, Bauman A, Hensley MJ et al. Self management education and regular practitioner review for adults with asthma. *Cochrane database Syst Rev* 2000; (2): CD 001117.
217. Simpson M, Buckman R, Steward M, Maguire P, Lipkin M, Novack D et al. Doctor-patient communication: the Toronto consensus statement. *Br Med J* 1991; 303: 1.385-1.387.
218. Coulter A. Paternalism or partnership? Patients have grown up-and there's no going back. *Br Med J* 1999; 319: 719-720.
219. Creer TL. Medication compliance and childhood asthma. En: Krasnegor NA, Epstein L, Johnson SB, Yaffe SJ, eds. *Developmental aspects of health compliance behavior*. Hittsdale, NS: Lawrence Associate, 1993; 303-333.
220. Creer TL, Backial M, Burns KL. Living with asthma. I. Genesis and development of a self-management program for childhood asthma. *J Asthma* 1988; 25: 335-362.
221. Creer TL, Kotses H, Reynolds VC. Living with asthma: Part II. Beyond CARIH. *J Asthma* 1989; 26: 31-51.
222. Boulet L-P, Chapman KR, Green LW. Asthma education. *Chest* 1994; 106: 184S-196S.
223. Green LW, Frankish J. Theories and principles of health education applied to asthma. *Chest* 1994; 106: 219S-230S.
224. Beasley R, Cushley M, Holgate ST. A self help management plan in the treatment of adult asthma. *Thorax* 1989; 44: 200-204.
225. Ignacio García JM, González Santos P. Asthma self management education program by home monitoring of peak expiratory flow. *Am J Respir Crit Care Med* 1995; 151: 353-359.
226. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. *Respir Med* 2000; 94: 279-287.
227. Abramson MJ, Bailey MJ, Couper FJ, Driver JS, Drummer OH et al. Are asthma medications and management related to deaths from asthma? *Am J Respir Crit Care Med* 2001; 163: 12-18.
228. Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. *Chest* 1997; 112: 1.134-1.138.
229. Kendrick AH, Higgs CM, Whitfield MJ, Laszlo G. Accuracy of perception of severity of asthma: patients treated in general practice. *Br Med J* 1993; 307: 422-424.
230. Bijl-Hofland ID, Cloosterman SG, Folgering HT, Akkermans RP, van Schayck CP. Relation of the perception of airway obstruction to the severity of asthma. *Thorax* 1999; 54: 15-19.
231. Barnes PJ. Blunted perception and death from asthma. *N Engl J Med* 1994; 330: 1.383-1.384.
232. López-Viña A, del Castillo Arévalo F. Influence of peak expiratory flow monitoring on an asthma self-management education programme. *Respir Med* 2000; 94: 760-766.
233. Mullol J. Rinitis alérgica en el año 2000. Clasificación y tratamiento actualizado. *Arch Bronconeumol* 2000; 36: 605-607.
234. Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. *J Allergy Clin Immunol* 1999; 104: 301-344.
235. Sibbald B, Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. *Thorax* 1991; 46: 895-901.
236. Bousquet J, Cauwenberge P, Khaltaev N, in collaboration with the World Health Organization. Allergic rhinitis and its impact on asthma. ARIA Workshop Report. *J Allergy Clin Immunol* 2001; 108(5 Supl): 147-134.
237. Larsen K. The clinical relationship of nasal polyps to asthma. *Allergy Asthma Proc* 1996; 17: 243-249.
238. Lamblin C, Tillie-Leblond I, Darras J, Dubrulle F, Chevalier D, Cardot E et al. Sequential evaluation of pulmonary function and bronchial hyperresponsiveness in patients with nasal polyposis: a prospective study. *Am J Respir Crit Care Med* 1997; 155: 99-103.
239. Dykewicz MS, Finerman S. Executive Summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. *Ann Allergy Asthma Immunol* 1998; 81: 463-468.
240. Anderson SD. Exercise-induced asthma. En: Middleton E, Reed C, Ellis E, Adkinson NF, Yunginger JW, eds. *Allergy: Principles and practice*. 3.<sup>a</sup> ed. St. Louis: CV Mosby, 1988.
241. Drobic F. Tesis Doctoral. Unitat Docent Hospital de la Sta. Creu i de St. Pau. UAB Barcelona, 1993.
242. Godfrey S. Exercise induced asthma: clinical, physiological, and therapeutic implications. *J Allergy Clin Immunol* 1975; 56: 1-17.
243. Valencia A, Casan P, Perpiñá M, Sebastián MD. Normativa para los tests de provocación bronquial inespecífica. *Sociedad Española de Patología del Aparato Respiratorio. Arch Bronconeumol* 1998; 34: 36-44.
244. Anderson SD, Connolly NM, Godfrey S. Comparison of bronchoconstriction induced by cycling and running. *Thorax* 1971; 26: 396-401.
245. Bardagí S, Agudo A, González CA, Romero PV. Prevalence of exercise-induced airway narrowing in school children from a Mediterranean town. *Am Rev Respir Dis* 1993; 147: 1.112-1.115.
246. Wooley M, Anderson SD, Quigley BM. Duration of protective effect of terbutaline sulphate and cromolyn sodium a combination on exercise-induced asthma. *Chest* 1990; 97: 39-45.
247. Waalkens HJ, van Essen-Zanduliel EEM, Gerritsen J, Duiverman EJ, Knol K. The effect of an inhaled corticosteroid (budesonide) on exercise-induced asthma in children. *Eur Respir J* 1993; 6: 652-656.
248. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. *N Engl J Med* 1998; 339: 147-152.
249. World antidoping Agency. [www.wada-ama.org].
250. Wenzel SE, Szeffer SJ, Leung DYM, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe persistent asthma: persistent inflammation associated with high dose glucocorticoids. *Am J Respir Crit Care Med* 1997; 156: 737-743.
251. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. *Am J Respir Crit Care Med* 1999; 160: 1.532-1.539.
252. American Thoracic Society. Proceedings of the ATS Workshop on Refractory Asthma. Current understanding, recommendations, and unanswered questions. *Am J Respir Crit Care Med* 2000; 162: 2.341-2.351.
253. Nimmigadda SR, Spahn JD, Leung DY, Szeffer SJ. Steroid-resistant asthma: evaluation and management. *Ann Allergy Asthma Immunol* 1996; 77: 345-355.
254. Rodríguez-Jerez F, Plaza V, Tárrega J, Casan P, Rodríguez J. Función tiroidea y asma de difícil control. *Arch Bronconeumol* 1998; 34: 429-432.
255. Weissler JC. Syndromes of severe asthma. *Am J Med Sci* 2000; 319: 166-176.
256. Irwin RS, Curley FJ, French CL. Difficult-to-control asthma. Contributing factors and outcome of a systematic management protocol. *Chest* 1993; 103: 1.662-1.669.
257. Wenzel SE. Approach to severe asthma: experience of a national referral center. En: Holgate ST, Boushey H, Fabbri L, eds. *Difficult asthma*. Londres: Dunitz, 1999; 535-543.
258. ERS Task Force. Difficult/therapy-resistant asthma. The need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. *Eur Respir J* 1999; 13: 1.198-1.208.
259. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. *Eur Respir J* 1990; 3: 588-593.
260. Quirce Gancedo S, Sastre Domínguez J. Definición y clasificación. En: Sastre J, Quince S, eds. *Patología Respiratoria Alérgica Ocupacional*. Emisa, 2003; 17-22.
261. Bernstein DI, Bernstein IL. Occupational asthma. En: Middleton E, Reed CE, Ellis EF, Adkinson NF, Yunginger JW, Busse WW, eds. *Allergy: Principles and practice*. St. Louis: Mosby-Year Book, Inc., 1998; 963-980.
262. Fraj J, Duce F, Lezaun A. La prueba de provocación bronquial específica en el diagnóstico de asma ocupacional. *Arch Bronconeumol* 1997; 33: 444-449.

263. Zacharisen MC. Occupational asthma. *Med Clin North Am* 2002; 86: 951-971.
264. Nannini LJ. Asma potencialmente fatal. *Arch Bronconeumol* 1997; 33: 462-471.
265. Centers for Disease Control. Asthma-United States, 1980-1990. *JAMA* 1992; 268: 1.995-1.999.
266. Lang DM, Polansky M. Patterns of asthma mortality in Philadelphia from 1969 to 1991. *N Engl J Med* 1994; 331: 1.542-1.546.
267. Sears MR, Rea HH. Patients at risk for dying of asthma: New Zealand experience. *J Allergy Clin Immunol* 1987; 80: 477-481.
268. Campbell DA, McLennan G, Coates JR, Frith PA, Gluyas PA et al. A comparison of asthma deaths and near fatal-asthma attacks in South Australia. *Eur Respir J* 1994; 7: 490-497.
269. Mitchell I, Tough SC, Semple LK, Green FH, Hessel PA. Near-fatal asthma: a population-based study of risk factors. *Chest* 2002; 121: 1.407-1.413.
270. Miller BC. Depression and asthma: a potentially lethal mixture. *J Allergy Clin Immunol* 1987; 80: 481-486.
271. Yellowless PM, Ruffin RE. Psychological defences and coping styles in patients following a life-threatening attack of asthma. *Chest* 1989; 95: 1.293-1.303.
272. Strunk RC. Workshop on the identification of the fatality-prone patient with asthma. Summary of workshop discussion. *J Allergy Clin Immunol* 1987; 80: 455-457.
273. Turner MO, Noertjojo K, Vedal S et al. Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. *Am J Respir Crit Care Med* 1998; 157: 1.804-1.809.
274. Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV et al. Sudden-onset fatal asthma: a distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? *Am Rev Respir Dis* 1993; 148: 713-719.
275. Plaza V, Serrano J, Picado C, Sanchis J. Rapid-onset fatal and near-fatal asthma. Frequency, clinical characteristics and course. *Eur Respir J* 2002; 19: 846-852.
276. Plaza V, Serrano J, Picado C, Cosano J, Ancochea J et al. Características clínicas de las crisis de Asma de Riesgo Vital en los pacientes sensibilizados a *Alternaria alternata*. *Med Clin (Barc)* 2003; en prensa.
277. Kikuchi Y, Okabe S, Tamura G, Hida W, Homma M et al. Chemosensitivity and perception of dyspnoea in patients with a history of near-fatal asthma. *N Engl J Med* 1994; 330: 1.329-1.334.
278. Picado C. Classification of severe asthma exacerbations: a proposal. *Eur Respir J* 1996; 9: 1.775-1.778.
279. McFadden ER, Warren EL. Observations on asthma mortality. *Ann Intern Med* 1997; 127: 142-147.
280. Molfino NA, Nannini LJ, Rebusk AS, Slutsky AS. The fatality-prone asthmatic patient. Follow-up study after near-fatal attacks. *Chest* 1992; 101: 621-623.
281. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and prevention of death from asthma. *N Engl J Med* 2000; 343: 332-336.
282. Marquette CH, Saulnier F, Leroy O et al. Long-term prognosis of near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. *Am Rev Respir Dis* 1992; 146: 76-81.
283. Plaza V, Serrano J. Asma fatal o casi fatal. Experiencia española. *Arch Bronconeumol* 2000; 36: 13-18.
284. Kircher S. Variables affecting asthma course during pregnancy. *Ann Allergy Asthma Immunol* 2002; 89: 463-466.
285. Demisse K. Infant and maternal outcomes in the pregnancies of asthmatic women. *Am J Respir Crit Care Med* 1998; 158: 1.091-1.095.
286. Clifton VL. Alterations of placental vascular function in asthmatic pregnancies. *Am J Respir Crit Care Med* 2001; 164: 546-553.
287. Wendel PJ. Asthma treatment in pregnancy: a randomized controlled study. *Am J Obstet Gynecol* 1996; 175: 150-154.
288. Kallen B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. *Obstet Gynecol* 1999; 93: 392-395.
289. Harding SM. Gastroesophageal reflux and asthma: Insight into the association. *J Allergy Clin Immunol* 1999; 104: 251-259.
290. Diette GB, Krishnan JA, Dominici F, Haponik E, Skinner EA et al. Asthma in older patients. Factors associated with hospitalization. *Arch Intern Med* 2002; 162: 1.123-1.132.
291. Field SK, Sutherland LR. Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux? A critical review of the literature. *Chest* 1998; 114: 275-283.
292. Greenberger PA. Allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol* 2002; 10: 685-692.
293. de Gracia J, Álvarez A, Mata F, Guarner L, Vendrell M, Gadtner S, Cobos N. Fibrosis quística en adultos: estudio de 111 pacientes. *Med Clin (Barc)* 2002; 119: 605-609.
294. Otero I, Montero C, Blanco M, Valino P, Vereza H. Aspergilosis broncopulmonar alérgica pseudotumoral. *Arch Bronconeumol* 2000; 36: 351-353.
295. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. *N Engl J Med* 2000; 342: 756-762.
296. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. *Arthritis Rheum* 2000; 43: 414-419.
297. Orriols R, Roman A, Bosch J, Sampol G, Bernado L, Morell F. Síndrome de Churg-Strauss: 8 casos en los últimos 10 años. *Med Clin (Barc)* 1989; 92: 241-244.
298. Ríos JJ, Gómez J, Suárez I, Gutiérrez M, Vázquez JJ et al. Síndrome de Churg-Strauss. Nuestra experiencia en dos décadas. *Rev Clin Esp* 2000; 200: 597-601.
299. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. *Medicine (Baltimore)* 1999; 78: 26-37.
300. Noth I, Streck ME, Leff AR. Churg-Strauss syndrome. *Lancet* 2003; 361: 587-594.
301. Lilly CM, Churg A, Lazarovich M, Pauwels R, Hendeles L et al. Asthma therapies and Churg-Strauss syndrome. *J Allergy Clin Immunol* 2002; 109: S1-19.
302. Newman KB, Dubester SN. Vocal cord dysfunction: masquerader of asthma. *Semin Respir Crit Care Med* 1994; 15: 161-167.
303. Newman KB, Mason UG, Schmalig KB. Clinical features of vocal cord dysfunction. *Am J Respir Crit Care Med* 1995; 152: 1.382-1.386.
304. Morris MJ, Deal LE, Bean DR, Gorbach VX, Morgan JA. Vocal cord dysfunction in patients with exertional dyspnea. *Chest* 1999; 116: 1.676-1.682.
305. Landwehr LP, Wood RP, Blager FB, Milgrom H. Vocal cord dysfunction mimicking exercise-induced bronchospasm in adolescents. *Pediatrics* 1996; 98: 971-974.
306. Christopher KL, Wood RP II, Eckert RC et al. Vocal-cord dysfunction presenting as asthma. *N Engl J Med* 1983; 308: 1.566-1.570.
307. Ramírez RJ, León I, Rivera LM. Episodic laryngeal dyskinesia: clinical and psychiatric characterization. *Chest* 1986; 90: 716-721.
308. Gavin LA, Wamboldt M, Brugman S, Roesler TA, Wamboldt F. Psychological and family characteristics of adolescents with vocal cord dysfunction. *J Asthma* 1998; 35: 409-417.
309. Perkner JJ, Fennelly KP, Balkissoon R, Bartelson BB, Rutenber AJ, Wood RP 2nd et al. Irritant associated vocal cord dysfunction. *Occup Environ Med* 1998; 40: 136-143.
310. McFadden ER, Zawadzki DK. Vocal cord dysfunction masquerading as exercise induced asthma: a physiologic cause for «choking» during athletic activities. *Respir Crit Care Med* 1996; 153: 942-947.
311. Rundell KW, Spiering BA. Inspiratory stridor in elite athletes. *Chest* 2003; 123: 468-474.
312. Healey DE, Swift E. Paradoxical vocal cord dysfunction in an infant with stridor and gastroesophageal reflux. *Int J Pediatr Otorhinolaryngol* 1996; 34: 149-151.
313. Ayres JG, Gabbott PLA. Vocal cord dysfunction and laryngeal hyperresponsiveness: a function of altered autonomic balance? *Thorax* 2002; 57: 284-285.

314. Andronopoulos MG, Gallivan GJ, Gallivan KH. PYLM, PUCD, EPL, and irritable larynx syndrome: what are we taking about and how do we treat it? *J Voice* 2000; 14: 607-618.
315. Goldman J, Muers M. Vocal cord dysfunction and wheezing. *Thorax* 1991; 46: 401-404.
316. Perkins P, Morris MJ. Vocal cord dysfunction induced by methacholine challenge Testing. *Chest* 2002; 122: 1.988-1.993.
317. Bahrainwala AH, Simon MR. Wheezing and vocal cord dysfunction mimicking asthma. *Curr Opin Pulm Med* 2001; 7: 8-13.
318. Sullivan M, Heywood BM, Beukelmon DR. A treatment for vocal cord dysfunction in female athletes: an outcome study. *Laryngoscope* 2001; 111: 1.751-1.755.
319. Brugman SM, Simons SM. Vocal cord dysfunction: don't mistake it for asthma. *Physician Sports Med* 1998; 26: 63-74.
320. Brightling CE, Wars R, Lay K, Wardlaw AJ, Pavrd ID. Eosinophilic bronchitis is an important cause of chronic cough. *Am J Respir Crit Care Med* 1999; 160: 406-410.
321. Fujimura M, Ogawa H, Yasui M, Matsuda T. Eosinophilic tracheobronchitis and airway cough hypersensitivity in chronic non-productive cough. *Clin Exp Allergy* 2000; 30: 41-47.
322. Fujimura M, Ogawa H, Nishizawa Y, Nishi K. Comparison of atopic cough with cough variant asthma: is atopic cough a precursor of asthma? *Thorax* 2003; 58: 14-18.
323. GRASSIC. Effectiveness of routine self monitoring of peak flow in patients with asthma. Grampian Asthma study of integrated care. *Br Med J* 1994; 308: 564-567.
324. Martínez González A. Cómo organizar una consulta de asma y EPOC. En: Martín Zurro A, Argimon Pallas JM, Jiménez Villa J, eds. Atención al paciente con asma y EPOC en la consulta del médico de familia. 1.ª ed. Barcelona: Masson SA, 2002; 156-159.
325. Contel Segura JC. La atención a domicilio como modelo de atención compartida. *Aten Primaria* 2000; 25: 526-527.
326. Martín Zurro A. Compartir y coordinar la atención de los pacientes entre el hospital y la atención primaria. Algunas propuestas prácticas. *Aten Primaria* 2000; 26: 65-68.
327. Plaza V, Rodríguez Trigo G, Peiró M, Fernández S, Nolla T, Puig J et al. Grado de satisfacción de médicos de Atención Primaria y pacientes sobre un nuevo esquema asistencial neumológico extrahospitalario. *Arch Bronconeumol* 2003; 39: 57-61.
328. Taggart VS. Implementation of the guidelines: a patient's perspective. *Eur Respir Rev* 1995; 5: 112-115.

Edita:



©2003 Grupo Español para el Manejo del Asma (GEMA)  
Muntaner, 374, 4.º / 08006 Barcelona  
Tel.: 93 209 02 55 / Fax: 93 202 06 43  
edmayo@edicionesmayo.es

ISBN: 84-89980-95-0  
Depósito legal: B-28034-03  
Impresión: Euro-Gràfica Sant Vicenç, S.L.

Reservados todos los derechos. No se puede reproducir ninguna parte de esta publicación, ni almacenarla en cualquier sistema recuperable, ni transmitirla por ningún medio electrónico, mecánico, fotocopiado, en discos, ni por cualquier otra forma de transmisión de información, sin la previa autorización por escrito del titular del copyright.